Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

3.600 -0.120 (-3.22%)

Streaming Delayed Price Updated: 12:06 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today? ↗

November 21, 2023

Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of

Via Benzinga

Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson

November 21, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

November 01, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Recap: Can Fite Biofarma Q1 Earnings ↗

June 01, 2023

Via Benzinga

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

October 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

October 26, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 24, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Via Benzinga

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

October 09, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

September 27, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference

September 07, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

August 31, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

August 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

August 18, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

July 17, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at the Emerging Growth Conference on July 13, 2023

July 07, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

June 29, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

June 13, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston

June 02, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

June 01, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

May 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

May 15, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

May 09, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 05, 2023

Via Benzinga

Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding

May 02, 2023

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 02, 2023

Via Benzinga

Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

May 02, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization

April 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 13, 2023

It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 11, 2023

Via Benzinga

Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

April 10, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.